BJDX צמיחה צפויה ברווח נקי למניה השנה Bluejay Diagnostics Corp

Bluejay Diagnostics (BJDX) develops rapid tests for cardiology and oncology, which minimizes the risks of narrow specialization. The annual trend for net income per share reflects a trajectory where the parameter value equals 0.00. In-house production facilities operate seamlessly due to regular equipment calibration. Simultaneously, the company is reducing plastic usage and energy costs as part of its environmental strategy.

This metric measures the annual dynamics of earnings per share, reflecting the actual efficiency of value generation for shareholders. By analyzing year-over-year EPS growth rates on the GURU.Markets platform, an investor tracks the operational resilience of the business between quarterly reports. For Bluejay Diagnostics (BJDX), this indicator is critical, as the lack of profit and challenges with test commercialization create risks of a constant capital deficit.